Thursday 7 May, 2026
Introduction A priori model-informed precision dosing (MIPD) is a method to recommend an appropriate first dose based solely on the…
Read moreAbstracts
Modelling jointly viral dynamic and fever during H1N1 infections in non-human primates
Thursday 7 May, 2026
Introduction: Pre-clinical modeling of viral dynamics has provided key insights during the covid-19 pandemic (specificities of each variant, treatment efficacy…
Read moreTranslational PK/PD modelling of sofetabart mipitecan, an antibody-drug conjugate linked to exatecan via a novel cleavable polysarcosine linker
Thursday 7 May, 2026
Background Sofetabart mipitecan is a Fc-silent, FRα specific humanized IgG1 antibody-drug conjugate (ADC) linked to exatecan, a topo-I inhibitor, via…
Read moreProspective randomised controlled trial on model-informed precision dosing (MIPD) for ustekinumab and vedolizumab in inflammatory bowel diseases (MOVE-IT): A Bayesian framework incorporating parameter uncertainty
Thursday 7 May, 2026
Background Monoclonal antibodies (mAbs) such as infliximab, ustekinumab (UST), and vedolizumab (VDZ) represent effective treatment options for patients with inflammatory…
Read morePOPULATION PHARMACOKINETICS OF DELAMANID AND ITS MAIN METABOLITE DM-6705 IN BREASTMILK IN PATIENTS TREATED FOR RIFAMPICIN-RESISTANT TUBERCULOSIS
Thursday 7 May, 2026
Objectives: Delamanid, a nitroimidazole drug used in the treatment of rifampicin-resistant tuberculosis (RR-TB),[1] has limited pharmacokinetic data describing its distribution…
Read moreINTEGRATED MIXED EFFECTS ANALYSIS OF PHARMACOKINETICS OF RUXOLITINIB CREAM AND IMPLICATIONS ON ITS SAFETY PROFILE IN ADULT PATIENTS WITH ATOPIC DERMATITIS OR VITILIGO
Thursday 7 May, 2026
Objectives: Ruxolitinib (selective Janus kinase [JAK]1/JAK2 inhibitor) is available as a topical cream for the treatment of inflammatory skin diseases…
Read morePK/PD modelling and simulations of cambritaxestat-mediated inhibition of autotaxin-lysophosphatidic acid pathway in metastatic pancreatic cancer patients to inform Phase II dose selection
Thursday 7 May, 2026
Background: Autotaxin (ATX) is an enzyme involved in the synthesis of lysophosphatidic acid (LPA), which regulates cell proliferation, migration and…
Read morePopulation pharmacokinetic–based probability of target attainment analysis of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant enterobacterales infections
Thursday 7 May, 2026
Introduction: OP0595 (nacubactam) is a novel β-lactamase inhibitor with dual mechanisms of action: as an inhibitor of serine β-lactamases (classes…
Read moreAnatomy-level pharmacokinetics of an intrathecally administered ASO
Thursday 7 May, 2026
Objectives Antisense oligonucleotides (ASOs) have emerged as a promising therapeutic modality for disorders of the central nervous system (CNS) [1]….
Read morePharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy
Thursday 7 May, 2026
Introduction: Givinostat is an oral histone deacetylase inhibitor indicated for the treatment of Duchenne muscular Dystrophy (DMD) in patients aged…
Read more